Hybritech to rid itself of MAb R&D

After years of working to develop monoclonal antibodies for radioimmune therapy and in vivo imaging, the Hybritech Inc. division of Eli Lilly and Co. said it was discontinuing development and looking to license the technology.

Hybritech had submitted one product to the FDA: Hybri-CEAker, an imaging agent for the diagnosis of colon cancer, but is no longer pursuing development of the test, according to Lilly spokesperson David Pomfret. On the in vivo therapy side, no products had reached clinical trials...